BB Biotech AG : Q3 in negative territory, the holding continues its reallocation strategy
>Net loss of CHF 157m in Q3 - BB Biotech this morning announced its Q3 2024 results. The yield on the stock was in negative territory at -9.2% in CHF and -6.7% in € and was negative for the first 9 months of the year at -11% (dividend included). The performance of the portfolio in Q3 stood at -6.6% in CHF, -4.4% in € and -0.6% in $, underperforming the Nasdaq Biotech Index (+5% in $ in the period), but was virtually flat in the first 9 months of the year at +0.3% in ...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.